Supplementary Fig. 1. Relationship between striatal DAT density and PDRBD-PDRBD-RP. Only about half of the iRBD patients with abnormally elevated PDRBD-RP (blue square dots) showed abnormally decreased striatal $^{18}$F-FP-CIT binding, whereas the remaining iRBD patients (red square dots) showed normal $^{18}$F-FP-CIT binding. No iRBD patient showed a normal PDRBD-RP with an abnormally decreased striatal DAT binding. Abnormal changes were defined as changes greater than 2 SDs above the mean for normal data. DAT: dopamine transporter, $^{18}$F-FP-CIT: $^{18}$F-N-3-fluoropropyl-2β-carboxymethoxy-3β-(4-iodophenyl)-norepinephrine, iRBD: idiopathic rapid eye movement sleep behavior disorder, PDRBD: de novo Parkinson’s disease with probable rapid eye movement sleep behavior disorder, PDRBD-RP: de novo Parkinson’s disease with probable rapid eye movement sleep behavior disorder-related spatial covariance pattern.